| 万瑞,王海会.吡格列酮联合炔雌醇环丙孕酮对肥胖型PCOS疗效及血清HP、FABP、IGFBP-3的影响.[J].中南医学科学杂志.,2022,(6):930-933. |
| 吡格列酮联合炔雌醇环丙孕酮对肥胖型PCOS疗效及血清HP、FABP、IGFBP-3的影响 |
| Effect of pioglitazone combined with ethinylestradiol and cycloproprogesterone on the curative effect of obese PCOS and the serum levels of HP, FABP and IGFBP-3 |
| 投稿时间：2021-12-23 修订日期：2022-08-10 |
| DOI：10.15972/j.cnki.43-1509/r.2022.06.038 |
| 中文关键词: 吡格列酮 炔雌醇环丙孕酮 肥胖型PCOS HP FABP IGFBP-3 [ |
| 英文关键词:pioglitazone ethinylestradiol and cycloproprogesterone obese PCOS HP FABP IGFBP-3 |
| 基金项目: |
|
| 摘要点击次数: 483 |
| 全文下载次数: 385 |
| 中文摘要: |
| 目的探讨吡格列酮联合炔雌醇环丙孕酮对肥胖型多囊卵巢综合征(PCOS)疗效及血清触珠蛋白(HP)、脂肪酸结合蛋白(FABP)、胰岛素样生长因子结合蛋白-3(IGFBP-3)的影响。 方法选取肥胖型PCOS患者82例,随机等分为对照组(炔雌醇环丙孕酮)和联合组(吡格列酮+炔雌醇环丙孕酮)。比较两组治疗总有效率,治疗前后性激素[睾酮(TS)、雌二醇(E2)、黄体生成素(LH)、卵泡刺激素(FSH)]、糖脂代谢指标[甘油三酯(TG)、高密度脂蛋白胆固醇(HDLC)、空腹血胰岛素(FINS)、空腹血糖(FBG)],以及血清HP、FABP、IGFBP-3水平和不良反应情况。 结果联合组治疗总有效率高于对照组(P＜0.05)。治疗后,两组E2、TS、LH、FSH、TG、FBG、FINS、HP、FABP、IGFBP-3均低于治疗前,HDLC水平高于治疗前(P＜0.05)；且联合组改善较对照组更为显著(P＜0.05)。联合组不良反应发生率与对照组比较差异无显著性(P＞0.05)。 结论吡格列酮联合炔雌醇环丙孕酮治疗肥胖型PCOS疗效显著,可下调患者血清HP、FABP、IGFBP-3水平。 |
| 英文摘要: |
| To investigate the effect of pioglitazone combined with ethinylestradiol and cyclopropesterone on obese polycystic ovary syndrome (PCOS) and the effect of serum haptoglobin (HP), fatty acid binding protein (FABP) and insulin-like growth factor binding protein-3 (IGFBP-3). MethodsEighty two obese PCOS patients were randomly divided into control group (ethinylestradiol cycloproprogesterone) and combination group (pioglitazone + ethinylestradiol cycloproprogesterone). The effective rateof treatment, sex hormones (testosterone (TS), estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH)), glucose and lipid metabolism indexes (triglycerides (TG), high-density lipoprotein cholesterol (HDLC), fasting blood insulin (fins), fasting blood glucose (FBG)), serum HP, FABP, IGFBP-3 and adverse reactions were compared between the two groups before and after treatment. ResultsThe effective rate of the combined group was higher than the control group (P＜0.05). After treatment, E2, TS, LH, FSH, TG, FBG, fins, HP, FABP and IGFBP-3 in both groups were lower than those before treatment, and HDLC level was higher than that before treatment (P＜0.05); And the improvement of the combined group was more significant than the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions between the combined group and the control group (P＞0.05). ConclusionPioglitazone combined with ethinylestradiol and cycloproprogesterone has a significant effect on the treatment of obese PCOS, and can down regulate the serum levels of HP, FABP and IGFBP-3. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|